Abstract
Hepatitis C virus (HCV) infection is a major public health threat in Malaysia and haemodialysis is a known risk factor for its transmission. Sofosbuvir-based therapies were recently introduced in Malaysia to treat chronic HCV but evidence on its effectiveness to treat patients with end-stage kidney failure (ESKF) under usual clinical settings remains limited. We initiated the first effectiveness research in the country to evaluate the use of sofosbuvir-daclatasvir with or without ribavirin (SOF-DVC ± RBV) in the ESKF population to treat chronic HCV infection.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call